Pfizer Limited Bombay S.E.

Equities

PFIZER

INE182A01018

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:50 2024-04-19 am EDT 5-day change 1st Jan Change
4,120 INR +0.30% Intraday chart for Pfizer Limited -1.61% -3.49%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer CI
Pfizer Limited Appoints Amit Agarwal as Whole-Time Director, Designated as Executive Director ­Finance CI
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer CI
Pfizer Limited Receives an Order from Joint Commissioner of State Tax Basis the GST Audit Conducted for Uttar Pradesh State for the Financial Year 2018-19 CI
Pfizer Limited Receives an Order from Deputy Commissioner of State Tax Basis the GST Audit Conducted for the Financial Year 2018-19 CI
Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024 CI
Pfizer Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Pfizer Ltd. Names CFO MT
Pfizer CFO Retires MT
Pfizer Limited Announces Retirement of Mr. Milind Patil as Chief Financial Officer CI
Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023 CI
Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023 CI
Pfizer Sees Sharp Fall in Fiscal Q2 Net Profit MT
Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of Directors CI
Pfizer Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner Lead CI
Pfizer Limited Approves A Final Dividend for the Financial Year Ended March 31, 2023 CI
Pfizer Limited Announces Change in Management, Effective September 1, 2023 CI
Seagen's breast cancer therapy meets main goal in late-stage study RE
Pfizer Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Pfizer Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023 CI
Pfizer Limited Initiates Voluntary Recall Of Magnex 1gm, 2gm, Magnex Forte 1.5gm, 3gm, Zosyn 4.5gm and Magnamycin 250mg, 1gm, 2gm Injections CI
Pfizer Posts Higher Fiscal Q4 Net Profit MT
Pfizer's India unit posts 3% rise in Q4 profit RE
Pfizer Limited Recommends A Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 16, 2023 CI
Chart Pfizer Limited
More charts
Pfizer Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company has its own manufacturing facility at Goa. The Company has various independent contract/third party manufacturers based across India. Its product portfolio includes vaccine, anti-infectives, cardiac, pain, maternal nutrition, gastrointestinal, contraceptives, anti-inflammatory, nutrition and immunity, and respiratory. The Company's vaccine business is focused on Prevenar 13, a pneumococcal conjugate vaccine that is administered to infants who are six weeks and older as part of primary vaccination, toddlers, adolescents, adults, and elderly population. Its inflammation and immunology portfolio includes two advanced therapies, which cater to patients suffering from diseases related to chronic immune system such as rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis and ulcerative colitis.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Quarterly revenue - Rate of surprise